Osteoarthritis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for osteoarthritis. 168 active patents protecting 6 drugs from 4+ originators. First major cliff: 2030. Daily refresh.

6
Approved drugs
168
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Osteoarthritis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Boehringer Ingelheim 97 patents Pfizer Inc. (originally Searle/Pharmacia) 37 patents Hisamitsu Pharmaceutical Co., Inc 14 patents Generic (originally Boots Group) 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating osteoarthritis. Each bar = one year. Y-axis scaled to peak year (80 patents).

12
27
1
28
17
29
35
30
1
31
4
32
2
33
4
35
80
36
3
38
2
39
4
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Mobic
MELOXICAM
 Boehringer Ingelheim 97 59 — 2030-05-26
Arthrotec
Diclofenac Sodium
 Pfizer 24 73 — 2027-03-22
Voltaren
DICLOFENAC
 Hisamitsu Pharmaceutical Co., Inc 14 57 — 2030-04-23
Advil
ibuprofen
 Generic (originally Boots Group) 14 70 — 2029-09-30
Celebrex
celecoxib
 Pfizer Inc. (originally Searle/Pharmacia) 13 51 — 2030-04-19
Indocin Sr
INDOMETHACIN
 — 6 56 — 2030-04-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8946292 Arthrotec method of use 80 2027-03-22
8871809 Arthrotec method of use 80 2027-10-17
8563613 Arthrotec method of use 80 2027-10-17
8252838 Arthrotec method of use 80 2028-04-21
11478488 Celebrex method of use 76 2030-04-19
11806400 Advil method of use 76 2032-03-16
11806400 Advil method of use 76 2032-03-16
9220784 Arthrotec method of use 75 2027-10-17
9168305 Arthrotec method of use 75 2027-10-17
9339552 Arthrotec method of use 75 2027-10-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12059423 Mobic composition of matter 5 2040-07-19
10245276 Celebrex composition of matter 10 2030-04-19
8598152 Celebrex composition of matter 10 2030-04-19
9012440 Celebrex composition of matter 10 2030-04-19
9649318 Mobic formulation 30 2035-03-31
9649318 Mobic formulation 30 2035-03-31
9526734 Mobic formulation 30 2033-03-31
9526734 Mobic formulation 30 2033-03-31
8545879 Mobic formulation 36 2030-08-31
8545879 Mobic formulation 36 2030-08-31

Related